Evidence-based therapy for cutaneous sarcoidosis

Clinics in Dermatology

Volumn 25, Issue 3, 2007, Pages 334-340

  Baughman, Robert P ^a   Lower, Elyse E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; CALCITONIN; CHLOROQUINE; CORTICOSTEROID; CYTOTOXIC AGENT; ETANERCEPT; FOLINIC ACID; FUMARIC ACID DERIVATIVE; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; INFLIXIMAB; LEFLUNOMIDE; MECLOPHENYLATE; METHOTREXATE; MINOCYCLINE; PLACEBO; PREDNISONE; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; BONE MARROW TOXICITY; CONSTIPATION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIZZINESS; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA NODOSUM; EVIDENCE BASED PRACTICE; EYE DISEASE; EYE TOXICITY; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; IRRITABILITY; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; MOOD DISORDER; MOUTH LESION; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SYSTEMATIC REVIEW; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ANTIMALARIALS; EVIDENCE-BASED MEDICINE; HUMANS; METHOTREXATE; MINOCYCLINE; SARCOIDOSIS; SKIN DISEASES; THALIDOMIDE;

EID: 34249797589     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2007.03.011     Document Type: Article

References (86)

1. Baughman R.P., and Selroos O. Evidence-based approach to the treatment of sarcoidosis. In: Gibson P.G., Abramson M., Wood-Baker R., Volmick J., Hensley M., and Costabel U. (Eds). Evidence-based respiratory medicine (2005), Blackwell Publishing Ltd, Malden 491-508
2. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 16 (1999) 149-173
3. Siltzbach L.E. Effects of cortisone in sarcoidosis: a study of thirteen patients. Am J Med 12 (1952) 139-160
4. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydrocolloid occlusive dressing. Acta Derm Venereol 72 (1992) 69-71
5. Fisher A.A. Sarcoid-like periocular dermatitis due to strong topical corticosteroids: prompt response to treatment with tetracycline. Cutis 40 (1987) 95-96
6. Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 94 Suppl 12 (1976) 51-58
7. Paramothayan N.S., Lasserson T.J., and Jones P.W. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev CD001114 (2005)
8. Mana J., Gomez V.C., Montero A., et al. Lofgren's syndrome revisited: a study of 186 patients. Am J Med 107 (1999) 240-245
9. Neville E., Walker A.N., and James D.G. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 208 (1983) 525-533
10. Baughman R.P., Judson M.A., Teirstein A., et al. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 99 (2006) 307-315
11. Rizzato G., Montemurro L., and Colombo P. The late follow-up of chronic sarcoid patients previously treated with corticosteroids. Sarcoidosis 15 (1998) 52-58
12. Gottlieb J.E., Israel H.L., Steiner R.M., Triolo J., and Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 111 (1997) 623-631
13. Baughman R.P., Iannuzzi M.C., Lower E.E., et al. Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19 (2002) 198-204
14. Cox C.E., Donohue J.F., Brown C.D., Kataria Y.P., and Judson M.A. The sarcoidosis health questionnaire. A new measure of health-related quality of life. Am J Respir Crit Care Med 168 (2003) 323-329
15. Adler R.A., Funkhouser H.L., Petkov V.I., and Berger M.M. Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 325 (2003) 1-6
16. Rizzato G., Tosi G., Mella C., Montemurro L., Zanni D., and Sisti S. Prednisone-induced bone loss in sarcoidosis: a risk especially frequent in postmenopausal women. Sarcoidosis 5 (1988) 93-98
17. Rizzato G. Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 53 (1998) 425-429
18. Adler R.A., and Hochberg M.C. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 163 (2003) 2619-2624
19. Rizzato G., Fraioli P., and Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax 50 (1995) 555-559
20. Rizzato G., and Montemurro L. Reversibility of exogenous corticosteroid-induced bone loss. Eur J Respir 6 (1993) 116-119
21. Gallacher S.J., Fenner J.A., Anderson K., et al. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. Thorax 47 (1992) 932-936
22. Gonnelli S., Rottoli P., Cepollaro C., et al. Prevention of corticosteroid-induced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61 (1997) 382-385
23. Montemurro L., Schiraldi G., Fraioli P., Tosi G., Riboldi A., and Rizzato G. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 49 (1991) 71-76
24. Maksymowych W., and Russell A.S. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 16 (1987) 206-221
25. Hirsch J.G. Experimental treatment with chloroquine. Am Rev Respir Dis 84 (1961) 52-58
26. Siltzbach L.E., and Teirstein A.S. Chloroquine therapy in 43 patients with intrathoracic and cutaneous sarcoidosis. Acta Med Scand 425 (1964) 302S-308S
27. Morse S.I., Cohn Z.A., Hirsch J.G., and Shaedler R.W. The treatment of sarcoidosis with chloroquine. Am J Med 30 (1961) 779-784
28. Paramothayan S., Lasserson T., and Walters E.H. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev CD003536 (2003)
29. Jones E., and Callen J.P. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 23 (1990) 487-489
30. Zic J., Horowitz D., Arzubiaga C., and King L. Treatment of cutaneous sarcoidosis with chloroquine: review of the literature. Arch Dermatol 127 (1991) 1034-1040
31. Liedtka J.E. Intralesional chloroquine for the treatment of cutaneous sarcoidosis. Int J Dermatol 35 (1996) 682-683
32. Bartel P.R., Roux P., Robinson E., and Anderson I.F. Visual function and long-term chloroquine treatment. South African J Med 84 (1994) 32-34
33. Jones S.K. Ocular toxicity and hydroxychloroquine: guidelines for screening. Br J Dermatol 140 (1999) 3-7
34. Mazzuca S.A., Yung R., Brandt K.D., Yee R.D., and Katz B.P. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol 21 (1994) 59-63
35. Silman A., and Shipley M. Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. Br J Rheumatol 36 (1997) 599-601
36. Baughman R.P., Winget D.B., and Lower E.E. Prospective, randomized, double blind trial of methotrexate as a steroid sparing agent for sarcoidosis: analysis of first 25 patients. Am J Respir Crit Care Med 155 (1997) A944
37. Lower E.E., and Baughman R.P. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med 155 (1995) 846-851
38. Vucinic V.M. What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 8 (2002) 470-476
39. Dev S., McCallum R.M., and Jaffe G.J. Methotrexate for sarcoid-associated panuveitis. Ophthalmology 106 (1999) 111-118
40. Samson C.M., Waheed N., Baltatzis S., and Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108 (2001) 1134-1139
41. Lower E.E., Broderick J.P., Brott T.G., and Baughman R.P. Diagnosis and management of neurologic sarcoidosis. Arch Intern Med 157 (1997) 1864-1868
42. Rajendran R., Theertham M., Salgia R., and Muthuswamy P. Methotrexate in the treatment of cutaneous sarcoidosis. Sarcoidosis 11 (1994) S335-S338
43. Veien N.K. Cutaneous sarcoidosis: prognosis and treatment. Clin Dermatol 4 (1986) 75-87
44. Gedalia A., Molina J.F., Ellis G.S., Galen W., Moore C., and Espinoza L.R. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr 130 (1997) 25-29
45. Henderson C.A., Ilchyshyn A., and Curry A.R. Laryngeal and cutaneous sarcoidosis treated with methotrexate. J R Soc Med 87 (1994) 632-633
46. Webster G.F., Razsi L.K., Sanchez M., and Shupack J.L. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol 24 (1991) 451-454
47. Veien N.K., and Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol 97 (1977) 213-216
48. Lower E.E., Smith J.T., Martelo O.J., and Baughman R.P. The anemia of sarcoidosis. Sarcoidosis 5 (1988) 51-55
49. Morgan S.L., Baggott J.E., Vaughn W.H., et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 121 (1994) 833-841
50. Erickson A.R., Reddy V., Vogelgesang S.A., and West S.G. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis & Rheumatism 38 (1995) 1115-1119
51. Kremer J.M., Alarcon G.S., Lightfoot Jr. R.W., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37 (1994) 316-328
52. Hassan W. Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists. Ann Rheum Dis 55 (1996) 273-275
53. Roenigk H.H., Auerbach R., Mailbach H.I., and Weinstein G.D. Methotrexate guidelines revised. J Am Acad Dermatol 6 (1982) 145-155
54. Baughman R.P., Weber F.L., Bejarano P.B., Koehler A., and Lower E.E. Methotrexate for chronic sarcoidosis: hepatotoxicity assessed by liver biopsy. Am J Respir Crit Care Med 159 (1999) A342
55. Zisman D.A., McCune W.J., Tino G., and Lynch III J.P. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 243-252
56. Hargreaves M.R., Mowat A.G., and Benson M.K. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 47 (1992) 628-633
57. Baughman R.P., and Lower E.E. Alternatives to corticosteroids in the treatment of sarcoidosis. Sarcoidosis 14 (1997) 121-130
58. Baughman R.P., and Lower E.E. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 21 (2004) 43-48
59. Wu J.J., Huang D.B., Pang K.R., Hsu S., and Tyring S.K. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 153 (2005) 254-273
60. Perri III A.J., and Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J 9 (2003) 5
61. Baughman R.P., and Lower E.E. Newer therapies for cutaneous sarcoidosis: the role of thalidomide and other agents. Am J Clin Dermatol 5 (2004) 385-394
62. Baughman R.P., Judson M.A., Teirstein A.S., Moller D.R., and Lower E.E. Thalidomide for chronic sarcoidosis. Chest 122 (2002) 227-232
63. Carlesimo M., Giustini S., Rossi A., Bonaccorsi P., and Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32 (1995) 866-869
64. Lee J.B., and Koblenzer P.S. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 39 (1998) 835-838
65. Nguyen Y.T., Dupuy A., Cordoliani F., et al. Treatment of cutaneous sarcoidosis with thalidomide. J Am Acad Dermatol 50 (2004) 235-241
66. Oliver S.J., Kikuchi T., Krueger J.G., and Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 102 (2002) 225-236
67. Rousseau L., Beylot-Barry M., Doutre M.S., and Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 134 (1998) 1045-1046
68. Ghobrial I.M., and Rajkumar S.V. Management of thalidomide toxicity. J Support Oncol 1 (2003) 194-205
69. Bachelez H., Senet P., Cadranel J., Kaoukhov A., and Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 137 (2001) 69-73
70. Eishi Y., Suga M., Ishige I., et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of Japanese and European patients with sarcoidosis. J Clin Microbiol 40 (2002) 198-204
71. Kalish R.S., and Koujak S. Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. Clin Immunol 113 (2004) 270-277
72. Kloppenburg M., Verweij C.L., Miltenburg A.M., et al. The influence of tetracyclines on T cell activation. Clin Exp Immunol 102 (1995) 635-641
73. Shapiro L.E., Knowles S.R., and Shear N.H. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 133 (1997) 1224-1230
74. Breuer K., Gutzmer R., Volker B., Kapp A., and Werfel T. Therapy of noninfectious granulomatous skin diseases with fumaric acid esters. Br J Dermatol 152 (2005) 1290-1295
75. Nowack U., Gambichler T., Hanefeld C., Kastner U., and Altmeyer P. Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters. BMC Dermatol 2 (2002) 15
76. Frizzell B., Stith M., and Jenrette J. Management of treatment-resistant cutaneous sarcoidosis with radiation. Am J Clin Oncol 25 (2002) 573-575
77. Grema H., Greve B., and Raulin C. Scar sarcoidosis-treatment with the Q-switched ruby laser. Lasers Surg Med 30 (2002) 398-400
78. Katoh N., Mihara H., and Yasuno H. Cutaneous sarcoidosis successfully treated with topical tacrolimus. Br J Dermatol 147 (2002) 154-156
79. Baughman R.P., and Lower E.E. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18 (2001) 70-74
80. Doty J.D., Mazur J.E., and Judson M.A. Treatment of sarcoidosis with infliximab. Chest 127 (2005) 1064-1071
81. Mallbris L., Ljungberg A., Hedblad M.A., Larsson P., and Stahle-Backdahl M. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 48 (2003) 290-293
82. Haley H., Cantrell W., and Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 150 (2004) 146-149
83. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., and Benticuaga M.N. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol (2005) 1-2
84. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
85. Baughman R.P., Lower E.E., Bradley D.A., Raymond L.A., and Kaufman A.H. Etanercept for refractory sarcoidosis: results of a double blind randomized trial. Chest 128 (2005) 1062-1067
86. Baughman R.P., Drent M., Kavuru M.S., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174 (2006) 795-802